Accelerating patient-led neurodegenerative and oncology research for enabling expansive digital phenotyping, clinical state predictions and outcomes measurement.

DigiBio enables pharmaceutical companies, research institutes, and physicians to collect digital biomarker data across all clinical trials and therapeutic areas. DigiBio is a HIPAA-compliant, cloud-based mobile and web platform which reduces the time it takes to design, implement and manage clinical trials while reducing trial cost and enhancing data quality.

Biofourmis brings the right care to every person, no matter where they are. The company’s AI-driven solution collects and analyzes over 120 biomarkers in real time and identifies shifts that require proactive interventions. This vital innovation enables Biofourmis to offer people everywhere connected access to hospital-level services, virtual provider networks for remote care, and life-changing clinical trials—all without leaving their homes. Trusted by leading health systems, payers, biopharma companies and patients alike, Biofourmis’ connected platform improves patient outcomes, prevents hospitalization readmissions, accelerates drug development, and closes critical gaps in care—with the goal of making science smarter, healthcare simpler, and patients healthier. Biofourmis is a global technology company enabling care delivery, with headquarters in Boston with key offices in Singapore and India. For more information, visit biofourmis.com and follow Biofourmis on LinkedIn, Twitter and YouTube.